Sino Biopharmaceutical (SMZ1) Financial Statements
Sino Biopharmaceutical Financial Overview
Sino Biopharmaceutical's market cap is currently $9.78B. The company's EPS TTM is $0.13; its P/E ratio is 31.03; and it has a dividend yield of 2.30%. Sino Biopharmaceutical is estimated to report earnings on April 1, 2027, and the estimated EPS forecast is $0.01. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 31.83B | $ 28.87B | $ 26.20B | $ 26.03B | $ 26.86B |
| Gross Profit | $ 26.13B | $ 23.53B | $ 21.21B | $ 21.54B | $ 21.53B |
| Operating Income | $ 6.95B | $ 6.14B | $ 5.67B | $ 5.59B | $ 5.16B |
| EBITDA | $ 7.50B | $ 6.49B | $ 6.98B | $ 6.69B | $ 19.87B |
| Net Income | $ 2.34B | $ 3.50B | $ 2.33B | $ 2.54B | $ 14.61B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 22.96B | $ 14.60B | $ 14.12B | $ 16.92B | $ 15.79B |
| Total Assets | $ 76.04B | $ 65.41B | $ 63.60B | $ 64.06B | $ 60.54B |
| Total Debt | $ 16.08B | $ 9.78B | $ 12.58B | $ 13.98B | $ 12.12B |
| Net Debt | $ 3.90B | $ 214.26M | $ 3.13B | $ 5.33B | $ 2.52B |
| Total Liabilities | $ 33.92B | $ 22.63B | $ 25.43B | $ 26.12B | $ 22.81B |
| Stockholders' Equity | $ 30.68B | $ 31.96B | $ 30.47B | $ 29.75B | $ 30.29B |
| Cash Flow | |||||
| Free Cash Flow | $ 7.59B | $ 5.22B | $ 4.36B | $ 4.56B | $ 3.47B |
| Operating Cash Flow | $ 9.29B | $ 6.62B | $ 6.07B | $ 6.27B | $ 5.37B |
| Investing Cash Flow | $ -12.41B | $ -1.71B | $ -756.98M | $ -4.07B | $ -2.52B |
| Financing Cash Flow | $ 4.16B | $ -6.32B | $ -6.55B | $ -3.19B | $ -3.23B |
Currency in CNY
